Evolus Inc. (EOLS)
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evolus: The Injectable Platform Is Becoming The Real Moat
Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics.
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus, Inc. (EOLS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.24 per share a year ago.
Evolus Q2 Earnings Call Highlights
Evolus NASDAQ: EOLS reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations.
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for standing by.
